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Abstract
Rapid and accurate detection and identification of viruses causing respiratory tract infections is important for patient care
and disease control. Despite the fact that several assays are available, identification of an etiological agent is not possible in
,30% of patients suffering from respiratory tract diseases. Therefore, the aim of the current study was to develop a
diagnostic set for the detection of respiratory viruses with sensitivity as low as 1–10 copies per reaction. Evaluation of the
assay using a training clinical sample set showed that viral nucleic acids were identified in ,76% of cases. To improve assay
performance and facilitate the identification of novel species or emerging strains, cultures of fully differentiated human
airway epithelium were used to pre-amplify infectious viruses. This additional step resulted in the detection of pathogens in
all samples tested. Based on these results it can be hypothesized that the lack of an etiological agent in some clinical
samples, both reported previously and observed in the present study, may result not only from the presence of unknown
viral species, but also from imperfections in the detection methods used.
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Introduction
Respiratory infections are an important cause of morbidity and
mortality, with a worldwide disease burden estimated at almost
98,000,000 disability adjusted life years (DALYs) and more than
4,000,000 deaths per year [1,2]. Several studies show that
respiratory infections have the most prominent impact on the
pediatric population, and it is assumed that preschool children
experience 6–10 viral infections per year, while older children,
adolescents and adults experience 3–5 per year [3,4,5]. Clinical
presentation of viral respiratory infections depends heavily on
patient status and the pathogen involved, and may show a broad
variety of symptoms, including both upper (e.g. common cold,
rhinitis, sinusitis, otitis media) and lower respiratory symptoms
(e.g. pneumonia, bronchopneumonia, bronchitis, bronchiolitis,
tracheitis and croup). Rapid and accurate detection and
identification of viruses causing respiratory tract infections is
important for patient care and disease control as this significantly
decreases the length of hospitalization and reduces management
costs. Furthermore, detection and identification of etiological
agents enables the introduction of specific antiviral treatments and
appropriate isolation precautions in severe cases [6,7]. Despite
this, no etiological agent can be identified in ,30% of patients
suffering from respiratory tract diseases. Previous studies hypoth-
esized that this might be due to the presence of as yet unknown
viruses [8,9,10,11,12].
Virus detection and typing is a tedious task because the presence
of multiple viral species and strains blurs the image, and infection
with a wide range of pathogens may result in a similar clinical
outcome [13,14,15,16,17,18,19]. Numerous clinical virology
laboratories continue to employ diagnostic algorithms, which
incorporate antigen or culture-based methods. The latter have
several drawbacks in that they are technically demanding and
laborious. Furthermore, not all viruses replicate in cell culture (e.g.
human bocavirus and human coronavirus HKU1) and the panel
of susceptible cell lines is limited [20,21,22]. The undeniable
advantage of this approach is that the recovered viral strains are
valuable for further pathogen characterization and antiviral
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32582Table 1. Sequences of primers used for nested-PCR detection of respiratory pathogens.
Virus group Reaction Primer name Primer sequence
a
Product
length
b
Adenoviruses 1
st PCR Adeno_F1 TTCCCCATGGCBCACAACAC 481 bp
Adeno_R1 CCCTGGTAGCCRATRTTGTA
2
nd PCR Adeno_F2 TCCATYCCHTCKCGCAACTGGGC 302 bp
Adeno_R2 GAACCAGTCYTTGGTCATGTT
Influenza A 1
st PCR INF1_5a CAATYGAGGAGTGCCTGATTAA 92 bp
INF1_3a GCCHYARCTATYTYARTGCATGT
2
nd PCR INF2_5a CCTGATTAAYGATCCCTGGG 64 bp
INF2_3a YARTGCATGTKYNAGGAAGGAG
Influenza B 1
st PCR INFB_F1 GTCTGTTTCCAAAGATCAAAGGC 460 bp
INFB_R1 ATGGCTTCRTACCCAACCATAGAG
2
nd PCR INFB_F2 TCGRTTTATAGGAAGAGCAATGGC 177 bp
INFB_R2 TAGRTCTTCWATGTCTGCAATCCC
Enteroviruses 1
st PCR 5enter_pcr1 TCCGGCCCCTGAATGCGGCTAATC 187 bp
3enter_pcr1 TGGCCAATCCAATAGCTATATGG
2
nd PCR 5enter_pcr2 CCCTGAATGCGGCTAATCCYAAC 178 bp
3enter_pcr2 CCAATCCAATAGCTATATGGYAAC
Respiratory syncytial virus 1
st PCR hRSVFa1 CTCAGTGTAGGTAGAATGTTTGC 450 bp
hRSVRa1 GATATCTRTATAATCCACTTTGTTCATC
2
nd PCR hRSVFa2 TKACAAGATATGGTGATCTAGA 204 bp
hRSVRa2 TGTACWCCATGCAGTTCATC
Alpha
coronaviruses
1
st PCR CoV1F1 TACAGGGTCCTCCTGGTAGTG 461 bp
CoV1R1 GKCCTATAGCACACATACGTTG
2
nd PCR CoV1F2 GRGTTGAGTGTTATAGTGG 240 bp
CoV1R2 GGYTCCATAACACCTTTAG
Beta
coronaviruses
1
st PCR CoV2F1 TATTATGTTAAGCCTGGTGG 268 bp
CoV2R1 CCATCATCACTCAAAATCATC
2
nd PCR CoV2F2 ACTAGYAGTGGTGATGCA 244 bp
CoV2R2 TCATCACTCAAAATCATCATAC
Bocavirus 1
st PCR BoV_5a GGCAATWCTGTWTCTCATGTTCA 236 bp
BoV_3a CTGTGAATGWGTAGGACAAAGG
2
nd PCR BoV_5b CAGCTAAATTTTATGAAACAACT 160 bp
BoV_3b CCAAGAGGAAATGAGTTTGGAA
Parainfluenza 1 1
st PCR PI_5a TTCTGGAGATGTCCCGTAGG 294 bp
PI_3a TCCTGTTGTCGTTGATGTCA
2
nd PCR PI_5b CCYYTACTGAGCAACAACCC 265 bp
PI_3b TTGTCGTTGATGTCATAGGT
Parainfluenza 2 1
st PCR PII_Fa CGAACTGCCACAATTCTTGG 420 bp
PII_Ra ATGTTGCTGAGGGGATAAAGC
2
nd PCR PII_Fb CTATGTTCAAGTATTCTTCATGA 272 bp
PII_Rb ATCATGCAGAAGCAGATTTCC
Parainfluenza 3 1
st PCR PIII_Fa AACTGTAAACTCAGACTTGGTAC 345 bp
PIII_Ra TATTGGATGTTCAAGACCTCC
2
nd PCR PIII_Fb GACTTGGTACCTGACTTAAATCC 278 bp
PIII_Rb TATCCCTGGTCCAACAGATGG
Human metapneumovirus 1
st PCR hMPV_F1 AARGAAAGAGAATTAAGTGTAGG 405 bp
hMPV_R1 TTGTTTCTGGTGGTGCATGTC
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for both detection and typing of pathogens in clinical samples or in
cell culture. Until now, several assays have been developed,
although high variability of viruses may pose a problem and lead
to false-negative results [17,25,26]. Indisputably, the most sensitive
and specific methods for detection of respiratory viruses are
molecular techniques [17,27,28,29].
Molecular methods may be roughly divided into sensitive and
specific assays such as real-time PCR or loop-mediated isothermal
amplification (LAMP) methods, and techniques with broad
specificity that are capable of detecting a wide variety of
pathogens. The latter group includes sequence-independent
methods (e.g. virus discovery based on cDNA-AFLP (VIDISCA),
Sequence-independent, single-primer amplification (SISPA), dif-
ferential display) [23,30,31,32,33]. The main disadvantage of such
an approach is that the sensitivity of the assays is limited. Further,
these methods are relatively laborious and high-throughput
analysis is unworkable. Some previously developed methods (e.g.
universal primers or microarray-based methods) are designed to
detect a broad range of targets combine, at least partially, the
advantages of these two approaches.
In the present study, human ciliated airway epithelial cell
cultures were used [34,35,36,37,38] in combination with a newly
developed set of nested PCR assays with broad specificity, which
are able to detect all known strains of respiratory viruses while
disregarding co-infections, genetic variability, and other material
contained in the clinical sample. Assay design was based on all
available sequence data for human respiratory viruses; therefore,
one may assume that they may enable the detection of previously
uncharacterized viral strains. The combination of this highly
sensitive culture system with a set of optimized molecular assays
should allow improved detection in clinical samples. This
hypothesis was verified using a set of clinical samples from
patients suffering from respiratory disease.
Results
Primer design and nested PCR
To design the sensitive and specific assays, all available
sequences from public databases were analyzed. Primer design
was based on sequence analysis facilitating the identification of
conserved regions within viral genomes. Primer blasting showed
no significant similarity to human genomic sequences and primer
pairs with the best thermodynamic parameters were chosen for
subsequent studies. The selected primer pairs are listed in Table 1.
Primers used for the detection of rhinoviruses have been previously
described and were found to be superior to any other assay [39].
Identification of viruses in cell culture supernatants and
clinical samples
All primer sets developed in silico were evaluated in an
experimental set-up. Briefly, primer sets were tested on positive
control material and the resulting products were analyzed on
agarose gels. Several optimization steps allowed the selection of
PCR conditions common for all reactions, including primer
concentration, amount of template, and PCR profile.
To test assay performance, a set of plasmids containing genetic
elements recognized by certain primers was prepared. All plasmids
were used as an input for nested PCR, and the resulting products
were analyzed on agarose gels. All reactions resulted in the
appearance of specific bands (Figure 1).
To show whether it is possible to detect viral pathogens in
clinical material, a set of virus culture supernatants, or clinical
isolates, was prepared, which contained HCoV-NL63, HCoV-
229E, HCoV-HKU1, RSV, influenza A and B viruses, parainflu-
enza 1, 2, 3 viruses, human bocavirus, human adenovirus, human
metapneumovirus or human respiratory enterovirus. Virus titers
were determined for all cultivable pathogens, and samples were
diluted to a TCID50 per mL of 1. For pathogens that were not
cultured, samples were diluted 10 times and used as an input for
amplification. Selected clinical samples from patients not present-
ing with obvious clinical symptoms of respiratory disease or tested
negative for respiratory viruses were used as dilution media. The
resulting PCR products were visualized on agarose gels and are
shown in Figure 2. Clearly, all positive samples yielded bands
corresponding in size to the predicted products. No inhibition of
Table 1. Cont.
Virus group Reaction Primer name Primer sequence
a
Product
length
b
2
nd PCR hMPV_F2 GAAACYTTAACAAAGTATGGTG 172 bp
hMPV_R2 GCTGTRGTTTCATATCTAAAGGC
adegenerated positions are marked with bold;
bexpected size calculated for a single strain.
doi:10.1371/journal.pone.0032582.t001
Figure 1. Amplification of viral nucleic acids using the
developed primer sets; A) Positive samples (plasmids contain-
ing template for PCR amplification) B) Negative controls. M: size
marker (GeneRuler 50–1000 bp DNA; Fermentas); CoV_1: HCoV-NL63,
CoV_2: HCoV-HKU1; RSV: respiratory syncytial virus; IAV: influenza A
virus; PIV: parainfluenza virus type 1, 2 or 3; BoV: bocavirus; AdV:
adenovirus type 4; IBV: influenza B virus; hMPV: human metapneumo-
virus; EV: echovirus 9. Analysis was performed on 1.5% agarose gel.
doi:10.1371/journal.pone.0032582.g001
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amplification was detected in the negative controls. Sequencing
confirmed the identity of the PCR products.
Assay sensitivity
Serial dilutions of control plasmids containing genetic elements
recognized by the PCRprimerswere used to determine the sensitivity
of each assay. Briefly, after assessment of plasmid concentration using
two independent methods (gel electrophoresis and spectrophotomet-
rically), the plasmidcopy number was set to 10
5 copies/mla n ds e r i a l l y
diluted to 10
0 copies/ml. One microliter of such a template was
further used as an input for the PCR reaction. The results presented
in Figure 3 show that the assay sensitivity varied from 1 to 10 copies
of template nucleic acids per reaction. Careful optimization showed
that the assay sensitivity could be further increased. By increasing the
primer concentration in the first PCR to 600 nM, a detection level of
1 copy per reaction was reached. Unfortunately at this sensitivity the
image becomes blurred and difficult to interpret due to the
appearance of non-specific products. No such distortion was seen
in the clinical samples, most likely because of the presence of nucleic
acids originating from eukaryotic cells that non-specifically bind to
dome of the primers (data not shown).
Cross-reactivity
To determine whether the newly designed assays were specific
for the selected pathogen, all primer pairs were tested for cross-
reactivity against all other respiratory pathogens included in the
study. Briefly, RNA or DNA was isolated from concentrated cell
culture samples or clinical specimens and subjected to reverse
transcription, where appropriate. The resulting cDNA was used as
an input for nested PCR using all the primer sets shown in
Table 1. No cross-reactivity was detected in any of the assays,
confirming high specificity of the PCR reactions (Figure 4).
Detection of viruses in clinical samples
A total of 34 samples were subjected to analysis. Briefly, RNA or
DNA was isolated and samples processed as described in ‘‘Materials
and Methods’’. Further, samples were used as an input for the
nested PCR developed within the current study. The results are
presented in Table 2 and show that an etiological agent was
identified in ,76% of cases, and the frequency of occurrence of
certain species was consistent with the available literature data [40].
Furthermore, two or more pathogens were identified in the same
sample in ,65% of cases (Table 3, Figure 5).
Improved detection of pathogens following the HAE
culture
As mentioned previously, an etiological agent cannot be found in
,30% of clinical specimens from patients suffering from respiratory
tract illnesses [8,9,10,11,12]. A similar detection rate was observed
in the current study; therefore, fully-differentiated HAE cultures
(Figure 6) were inoculated with clinical specimens that remained
undiagnosed by standard assays. A total of 8 samples were tested.
Apical washes werecollected following incubation for 72 h or 144 h
post-inoculation at 37uC. RNA or DNA from these samples was
isolated and submitted for nested PCR analysis. Combining the
sensitivity of the developed diagnostic sets with the potency of HAE
cultures resulted in viral pathogens being detected in all the tested
samples (Table 3, Figure 7).
Discussion
At present, the most sensitive and specific methods for
detection, typing and identification of viruses are based on
molecular biology techniques. Numerous molecular assays have
been described, though in silico analysis reveals that the majority
of these methods are based on the sequence of only a single viral
isolate, and that their performance in laboratory settings is
limited (data not shown). In the current study, a broad and
sensitive panel of assays based on a two-step nested PCR was
developed for the detection of a majority of human respiratory
viruses. Selected primer sets, designed based on complete
GenBank information, are complementary to 95–100% of the
sequences of archival and contemporary viral strains. Such an
approach limits the influence of intra–species sequence variability
and facilitates the detection of contemporary and (most likely)
Figure 2. Detection of respiratory viral pathogens in different clinical materials (nasal lavages, sputum, and bronchioalveolar
lavage (BAL)). M: size marker (GeneRuler 50–1000 bp DNA; Fermentas); CoV_1: HCoV-NL63, CoV_2: HCoV-HKU1; RSV: respiratory syncytial virus; IAV:
influenza A virus; PIV: parainfluenza virus type 1, 2 or 3; BoV: bocavirus; AdV: adenovirus type 4; IBV: influenza B virus; hMPV: human
metapneumovirus; EV: echovirus 9. Analysis was performed on 1.5% agarose gel.
doi:10.1371/journal.pone.0032582.g002
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considered not only as detection techniques but also as a basic
tool for virus discovery. The main disadvantage of developed tests
is that detection is limited to viruses that belong to specific viral
families/subfamilies, and they cannot be used for all viruses.
Furthermore, the diversity of viral species in combination with
their low load in clinical samples may result in false-negatives
[41]. This particular feature makes these assays inferior to
sequence-independent methods (e.g. VIDISCA), which can
detect unknown pathogens [23,42]. Then again, assays based
on degenerated primers offer far higher sensitivity than those
based on sequence-independent detection techniques.
The detection of unknown viral pathogens in respiratory clinical
material is difficult using sequence-independent virus discovery
methods, as the low viral load and high background signal from
cellular nucleic acids frequently hinders detection. Until now,
sequence independent virus discovery techniques were mostly used
for virus culture supernatants (as they contain highly concentrated
viral nucleic acids) [23,43], or for the discovery of previously
unknown DNA viruses [44,45,46]. Thus far, no study has
identified a novel human respiratory RNA virus using sequence
independent amplification techniques. Even though several
improvements have been proposed [47,48,49], the sensitivity of
these methods is inferior to that of nested or real-time PCR.
Figure 3. Sensitivity of the developed assays. Numbers at the top of the figure denote virus copy number per reaction. CoV: coronavirus; RSV:
respiratory syncytial virus; IAV: influenza A virus; PIV: parainfluenza virus type 1, 2 or 3; BoV: bocavirus; AdV: adenovirus type 4; IBV: influenza B virus;
hMPV: human metapneumovirus; EV: echovirus 9. GeneRuler 50–1000 bp DNA (Fermentas) marker was used as a size marker. Analysis was performed
on 1.5% agarose gel.
doi:10.1371/journal.pone.0032582.g003
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,76% of clinical samples, leaving ,24% of cases undiagnosed.
Such a detection rate is consistent with that in previously published
reports [8,9,10,11,12]. To test whether it was possible to type the
infectious agents in the remaining samples, molecular assays were
developed and coupled with ex vivo cell culture techniques based on
fully differentiated human airway epithelium.
HAE cultures constitute a semi-natural environment for the
replication of viral pathogens, and pre-amplification of viruses
contained in otherwise negative clinical samples resulted in the
detection of viral agent(s) in 100% of cases. This observation is
compliant with the fact that the HAE model is superior to any
other culture system in terms of amplifying respiratory viruses.
HAE cultures allow replication of majority of the respiratory viral
species, including those that cannot be cultured in cell lines.
Again, one may question whether using HAE cultures will bias
the results, as it is known that human metapneumovirus, for
example, does not replicate in such a model (unpublished
observation). This assumption is undoubtedly correct, although
as mentioned above, this culture model is superior for the majority
of respiratory viruses and is unrivalled in terms of virus discovery.
The system developed in the present study for the detection of
respiratory pathogens represents a two-stage screening system, in
which clinical samples can be tested for known viruses, and
samples that remain undiagnosed may be amplified in ex vivo HAE
cultures. Such amplification may result in enhanced detection of
viruses in clinical samples during the second round testing with
universal primers and, eventually, in the identification of obstacles
that hinder the detection of pathogens (e.g. strain variability,
presence of PCR inhibitors). Furthermore, these cultures may
serve as a source of input material for sequence-independent
amplification, which require high virus yield and good signal/
background ratios.
In conclusion, the present study describes a set of assays with
sensitivity as low as 1–10 copies per reaction that can be used in a
routine diagnostic laboratory. The obtained results clearly show
that the evaluated tests are highly specific and sensitive. Thorough
testing showed that the developed primer sets do not cross react
with other respiratory pathogens and are able to detect viruses in a
wide range of clinical samples. Further, HAE cultures can be used
for pre-amplification of the signal contained in the sample and to
facilitate detection of pathogens by standard PCR or sequence-
independent methods. Based on these observations, one may
hypothesize that the reported lack of an etiological agent in a
proportion of patients suffering from respiratory disease may result
not only from the presence of unknown viral species, but also from
a lack of sensitivity of the available assays. Further studies,
including VIDISCA analysis, will provide greater insights into the
epidemiology of different strains and species, and may possibly
allow the detection and identification of previously unknown
viruses.
Materials and Methods
Virus preparation, titration and culture
Virus stocks were generated by infecting HeLa cells (ATCC:
CCL-2) with adenovirus; RD cells (ATCC: CCL-136) with
enterovirus; LLC-MK2 cells (ATCC: CCL-7; kind gift from Lia
van der Hoek) with parainfluenza type 1, 2 and 3, HCoV-NL63,
hMPV and hRSV; and MDCK.2 cells (ATCC: CCL-2936) with
influenza A and B. In all the cases, cells were lysed after
appearance of the cytopathic effect by two freeze-thawing cycles.
The virus-containing fluid was aliquoted and stored at 280uC. A
control cell lysate from mock-infected cells was prepared in the
same manner as the virus stock.
Virus yield for all pathogens was assessed by titration on fully
confluent susceptible cells, according to Reed and Muench
formula [50]. Plates were incubated at 32uCo r3 7 uC, and the
cytopathic effect occurrence was scored using an inverted
microscope.
Human coronavirus 229E, parainfluenza 1 and 2 viruses, and
bocavirus originated directly from clinical samples processed in
Figure 4. Specificity of the developed assays. All primer pairs (names on top of the figure) were used to amplify all virus stocks included in the
study (names on the left side of each panel). M: size marker (GeneRuler 50–1000 bp DNA; Fermentas); CoV_1: HCoV-NL63, CoV_2: HCoV-HKU1; RSV:
respiratory syncytial virus; IAV: influenza A virus; PIV: parainfluenza virus type 1, 2 or 3; BoV: bocavirus; AdV: adenovirus type 4; IBV: influenza B virus;
hMPV: human metapneumovirus; EV: echovirus 9. Analysis was performed on 1.5% agarose gel.
doi:10.1371/journal.pone.0032582.g004
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echovirus 9, RSV, human parainfluenza 3 virus and human
adenovirus were kindly provided by Marcel Muller; human
coronavirus NL63 was a kind gift from Lia van der Hoek. Human
metapneumovirus and human coronavirus HKU1 were kindly
provided by Oliver Schildgen and Astrid Vabret, respectively.
Influenza B virus was successfully isolated in our laboratory in the
past.
Human airway epithelium cultures
Human tracheobronchial epithelial cells were obtained from
airway specimens resected from patients undergoing surgery under
Silesian Center for Heart Diseases – approved protocols. This
study was approved by the bioethical committee of the Medical
University of Silesia in Katowice, Poland (approval no: KNW/
0022/KB1/17/10 dated on 16.02.2010). A written informed
consent was obtained from all patients. Primary cells detached
from human bronchi and trachea with pronase E were expanded
on collagen-coated (collagen type IV, Sigma aldrich) plastic in
bronchial epithelial growth media (BEGM) to generate passage 1
cells and plated at density of 3610
5 cells per well on permeable
Transwell inserts (6.5-mm-diameter; Corning Transwell-Clear)
supports in BEGM. Cells were cultured at 37uC in presence of 5%
CO2 until confluence. Human airway epithelium (HAE) cultures
were generated by changing the media to Air Liquid Interface
media (ALI) and provision of an air-liquid interface for 6 to 8
weeks to form well-differentiated, polarized cultures that resemble
in vivo pseudostratified mucociliary epithelium. All procedures were
performed as previously described [34].
Histology and immunohistochemistry
For visualization of HAE structures, cultures on Transwell
inserts were washed one time with 16PBS and fixed with 400 ml
of 4% paraformaldehyde in 16PBS. Samples were incubated for
15 min at room temperature and membranes were detached from
the plastic frame. Subsequently, membranes were washed with 16
PBS, dehydrated in a gradient of ethanol and xylene, paraffin
embedded, sectioned (5 mm) and mounted on silanised glass slides.
Prior to staining, slides were deparaffinized with xylene and
rehydrated in ethanol.
Morphology of HAE cultures was visualized by means of
standard haematoxylin and eosin method. For fluorescence
microscopy, slides were incubated consecutively in 0.2% Tween
20 (20 min, room temperature) and 2% bovine serum albumin
Table 2. Detection of respiratory viruses in clinical samples.
Pathogen Cases [no (%)]; PCR
a
Cases [no (%)];
HAE+PCR
b
alphacoronavirus 1 (2.94%) 4 (11.76%)
betacoronavirus 2 (5.88%) 3 (8.82%)
RSV 0 (0.00%) 0 (0.00%)
influenza A 6 (17.65%) 6 (17.65%)
influenza B 2 (5.88%) 2 (5.88%)
parainfluenza 1 1 (2.94%) 2 (5.88%)
parainfluenza 2 0 (0.00%) 2 (5.88%)
parainfluenza 3 3 (8.82%) 3 (8.82%)
bocavirus 0 (0.00%) 0 (0.00%)
adenowirus 3 (8.82%) 3 (8.82%)
hMPV 0 (0.00%) 0 (0.00%)
enterovirus 11 (32.35%) 4 (47.06%)
rhinovirus 12 (35.29%) 9 (47.06%)
Total 26 (76.47%) 34 (100%)
anumber of clinical samples tested positive with PCR;
bnumber of clinical samples tested positive with PCR and pre-amplified on HAE
cultures.
doi:10.1371/journal.pone.0032582.t002
Table 3. Detection of respiratory pathogens in clinical
samples.
Patient Detected pathogen [PCR
a]
Detected pathogen [HAE
cultures
b]
1 rhinowirus, betacoronavirus,
enterovirus, adenovirus
N.T.
d
2 rhinowirus, enterovirus N.T.
3 influenza A N.T.
4 N.D.
c enterovirus, alphacoronavirus
5 N.D. enterovirus, betacoronavirus,
rhinovirus
6 N.D. enterovirus, alphacoronavirus
7 rhinowirus, enterovirus N.T.
8 N.D. enterovirus, parainfluenza 2,
rhinovirus
9 rhinowirus N.T.
10 rhinowirus, parainfluenza 3,
influenza B
N.T.
11 enterovirus N.T.
12 rhinowirus, adenovirus N.T.
13 parainfluenza 1,enterovirus N.T.
14 rhinowirus, adenovirus N.T.
15 N.D. rhinovirus
16 N.D. enterovirus, parainfluenza 2
17 rhinowirus, alphacoronavirus N.T.
18 rhinowirus N.T.
19 Enterovirus N.T.
20 Enterovirus N.T.
21 rhinowirus N.T.
22 betacoronavirus N.T.
23 Enterovirus N.T.
24 rhinowirus, Influenza A N.T.
25 N.D. parainfluenza 1
26 influenza A, adenovirus N.T.
27 Enterovirus N.T.
28 influenza A N.T.
29 N.D. alphacoronavirus, rhinovirus
30 influenza A, adenovirus N.T.
31 rhinowirus, parainfluenza 3 N.T.
32 Enterovirus N.T.
33 parainfluenza 3, enterovirus N.T.
34 influenza A, influenza B N.T.
aclinical samples tested with PCR;
bclinical samples pre-amplified on HAE cultures, tested with PCR;
cN.D.: not detected;
dN.T.: not tested.
doi:10.1371/journal.pone.0032582.t003
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of b5-Tubulin and mucin 5AC samples were incubated with
mouse monoclonal anti-recombinant b5-Tubulin (Santa Cruz;
dilution 1:100) and mouse monoclonal anti-recombinant Mucin
5AC, Santa Cruz; dilution 1:50), respectively. Goat anti-mouse
IgG (H+L) Alexa Fluor 488 (Invitrogen; dilution 1:200;) was used
as a secondary antibody. Nuclear staining was performed using
Hoechst 33258 (Sigma-Aldrich; 0.5 mg/mL). Sections were
examined with fluorescent microscope (Nicon Eclipse
Ti).
Clinical samples
Clinical samples from adult patients with asthma exacerbations
were submitted to the Jagiellonian University Medical College,
Krakow, Poland. Samples (nasal washings obtained by the lavages)
were collected as a part of standard procedure for diagnosis of
respiratory pathogens. This study was approved by the Bioethical
Committee of the Jagiellonian University in Krakow, Poland
(approval no: KBET/68/B/2008 dated on 25.09.2008; extended
until 30.11.2012). A written informed consent was obtained from all
patients. Following the collection samples were stored at 280uC.
Figure 5. Detection of viruses in clinical material. Detection of respiratory viral pathogens in clinical specimens (nasal lavages). M:
size marker (GeneRuler 50–1000 bp DNA; Fermentas); PC: positive control; Clinical samples are denoted with consecutive numbers. Samples
considered to be positive are marked with ‘‘+’’ sign. CoV1: alphacoronavirus, CoV2: betacoronavirus; RSV: respiratory syncytial virus; IAV: influenza A
virus; PIV: parainfluenza virus type 1, 2 or 3; BoV: bocavirus; AdV: adenovirus; IBV: influenza B virus; hMPV: human metapneumovirus; EV: enterovirus.
Analysis was performed on 1.5% agarose gel.
doi:10.1371/journal.pone.0032582.g005
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In order to design primers that would recognize all strains of a
given virus, irrespectively of natural variability, all genomic
sequences available via GenBank were obtained. Sequences were
organized with BioEdit software and further aligned with
ClustalW script (http://www.ebi.ac.uk/). For influenza A se-
quence alignments, sets containing 500 sequences were generated,
due to limitations of the alignment software. Conserved sites in
sequence sets were identified with BioEdit and inspected by eye.
For larger data sets, a visual basic script was developed to identify
the presence of sites conserved in more than 95% of analyzed
genomes. All positions were further verified in terms of primer
quality and specificity with Blast server (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) and with OligoAnalyzer 3.1 (http://eu.idtdna.com/
analyzer/applications/oligoanalyzer/). In order to correct for
strain variability, 39 part of the primer was designed at the
conserved site, while 59 part was degenerated, if required.
Nucleic acid extraction
RNA from clinical samples and viral culture supernatants was
extracted using RNA mini kit (A&A Biotechnology, Gdynia,
Poland), according to manufacturer’s protocol. DNA was isolated
using Viral DNA/RNA mini kit (A&A Biotechnology, Gdynia,
Poland), according to manufacturer’s instructions. Isolated nucleic
acids were stored at 280uC.
Generation of plasmid-based positive controls
In order to develop positive controls that can be easily quantified,
a set of plasmids containing DNA fragment targeted by dedicated
primerswasprepared.Briefly,isolatedRNAwasreversetranscribed
with High Capacity cDNA Reverse Transcription (Applied
Biosystems), according to manufacturer instructions, using 15 ml
of the previously extracted RNA. Isolated DNA from samples
containing DNA viruses was used as input for PCR without any
processing. First PCR reaction was conducted as described below
and resulting mixtures were layered on 1.5% agarose gel. Following
gelseparationofDNAfragments, bandscorrespondinginsizetothe
expected products were extracted from the gel and total DNA was
purified with Gel-out kit (A&A Biotechnology, Gdynia, Poland).
DNA concentration was further assessed spectrophotometrically
and cloned with InsTAclone PCR Cloning kit (Fermentas) into
pTZ57R/T vector. After amplification in DH5a E. Coli and
plasmid isolation with Plasmid mini kit (A&A Biotechnology,
Gdynia, Poland), identity of cloned cDNA fragments was confirmed
with DNA sequencing. Subsequently, plasmid DNA was linearized
with EcoRI restriction enzyme (Fermentas), separated with gel
electrophoresis and purified from the gel, as described above. DNA
concentration was assessed spectrophotometrically and by gel
analysis and number of copies per mL was calculated. Generated
plasmids were further used as positive controls for PCR reaction.
Reverse transcription and PCR reactions
Isolated nucleic acids (reverse transcribed for RNA viruses) were
used as an input material for two-round PCR reaction with
selected primers. Amplification was carried out in a total volume of
10 ml with DreamTaq PCR Master Mix (Fermentas), in presence
of forward and reverse primers (1
st PCR: 200 nM each; 2
nd PCR:
600 nM each) and template DNA (1
st PCR: 2 ml; 2
nd PCR: 2 ml).
The first PCR (touch-down PCR protocol) cycling conditions
included initial denaturation for 3 minutes at 95uC followed by 13
cycles of 20 sec at 95uC, 30 sec at 68uC (which was decreased by
1uC per cycle), 40 sec at 72uC. A further 27 cycles of 20 sec at
95uC, 30 sec at 56uC, 40 sec at 72uC then followed and 5 min at
72uC for the final elongation.
For the nested PCR, reaction was prepared in the same
manner, with 2.0 ml of the 1
st PCR mixture as a template. The
cycling conditions for the nested PCR consisted of an initial
denaturation for 2 min at 95uC followed by 35 cycles of 20 sec at
95uC, 30 sec at 56uC, 40 sec at 72uC, and an additional 5 min at
72uC for final elongation. Following the nested PCR the whole
sample (10 ml) was analyzed on a 2.5% (influenza A assay) or 1.5%
(other assays) agarose gel and visualized with ethidium bromide.
Figure 6. HAE culture architecture. A) Haematoxylin and eosin
staining B) b-tubulin and nuclear staining, C) mucin 5AC and nuclear
staining. Images were obtained employing fluorescence microscope at
6006magnification; Scale bar: 25 mm.
doi:10.1371/journal.pone.0032582.g006
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In order to determine the sensitivity of each assay, serial
dilutions of linearized positive control plasmids were used in
concentrations ranging from 10
0–10
5 copies per reaction. PCR
and nested PCR were conducted as described above. Analysis was
performed with standard gel electrophoresis. Further, assays were
evaluated with cell culture material or clinical samples positive for
HCoV-NL63, HCoV-229E, HCoV-HKU1, RSV, influenza A
and B viruses, parainfluenza 1, 2, 3 viruses, human bocavirus,
adenovirus type 4, human metapneumovirus and human echovi-
rus 9. Virus stocks were diluted in culture media or clinical samples
tested negatively for all known pathogens, including sputum,
bronchioalveolar lavage, and nasal lavages.
Evaluation of assay specificity
Viral nucleic acids were isolated as described above and reverse
transcribed where appropriate. Concentrated viral samples were
tested with all primer sets by two-round PCR and validity of assays
was evaluated. Viruses used in this study include HCoV-229E,
HCoV-NL63, HCoV-HKU1, influenza A and B viruses, parain-
fluenza 1, 2, 3 viruses, bocavirus, RSV, human adenovirus, human
metapneumovirus and human echovirus 9.
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